"Similar to the survival rate in the 50s when actively treating elderly liver cancer patients"
Aug 12, 2024
In the case of elderly liver cancer patients, treatment is often abandoned, and a study found that if patients with liver cancer in their 70s are actively treated, they can achieve the same treatment effect as patients in their 50s.
Professor Lee Han-ah of the Department of Gastroenterology at Chung-Ang University Hospital, Professor Lee Sang-hun of International St. Mary's Hospital, and Professor Kim Do-young of Severance Hospital published a paper titled 「The efficiency of treatment for hepatocellular carcinoma in elderly patients」.
Professor Lee Han-ah's team compared and analyzed the survival rate (OS) according to the stage and treatment status and method of cancer by dividing 15,186 patients diagnosed with liver cancer in Korea from 2008 to 2017 into two groups: elderly patients aged 65 or older (average age 72 years, elderly patients) and non-aged patients under 65 years old (average age 54 years, non-elderly patients).
Among liver cancer patients, 25.2% of elderly patients did not receive any treatment and 16.7% of non-aged patients did not receive treatment, indicating that elderly patients often give up treatment.
However, it was found that among elderly liver cancer patients, those who received treatment had a longer average survival period than those who did not receive treatment (38.6 months vs. 22.3 months)
In particular, there was no significant difference in survival rates (66.0 months vs. 90.3 months) in elderly and non-aged patients who underwent surgery in intermediate-stage HCC and in elderly and non-aged patients who received transcatheter chemoembolization (TACE) treatment (36.5 months vs. 37.2 months), and in advanced-stage HCC, there was no significant difference in survival rates (28.4 months vs. 33.5 months) and chemotherapy (S) in elderly and non-aged patients who underwent transcatheter arterial therapy (TACE) (28.4 months vs. 33.5 months).3 months) were all found to be similar.
As a result, the research team confirmed that elderly liver cancer patients can achieve the same treatment effect as non-aged patients through active and patient-tailored treatment.
Professor Lee Han-ah of the Department of Gastroenterology at Chung-Ang University Hospital said "This study identified the current status of treatment for elderly liver cancer patients, which is increasing recently, and found that elderly liver cancer patients can achieve the same treatment effect as non-aged patients with active and customized treatment according to the patient's condition.""Even older people in their 70s and older who have been diagnosed with liver cancer, 40% of older patients with advanced liver cancer give up treatment despite having similar treatment effects as patients in their 50s."
Professor Lee Han-ah then explained, `In this study, it can be confirmed that elderly liver cancer patients who received active treatment have improved survival rates compared to those who did not receive treatment, and because they have the same survival rate as non-aged patients, even elderly people need to receive active treatment through carotid artery treatment or targeted cancer treatment and immunotherapy," he stressed.
Meanwhile, this research paper by Professor Lee Han-ah of the Department of Gastroenterology at Chung-Ang University Hospital was published in the Journal of Liver Cancer Society, and on June 29th, he won the JLC-Paper Award at the 2024 International Conference on Liver Week 2024 in recognition of the excellence of the paper.
Professor Lee Han-ah is a professional researcher in the field of chronic hepatitis B and metabolic abnormalities and consistently publishes research papers in world-renowned journals, and serves as an associate of the Publication Committee of the Korean Liver Association, an academic member of the Korean Liver Association, and a planning member, and is actively engaged in treatment and research activities in the field of liver disease.
Professor Lee Han-ah of the Department of Gastroenterology at Chung-Ang University Hospital, Professor Lee Sang-hun of International St. Mary's Hospital, and Professor Kim Do-young of Severance Hospital published a paper titled 「The efficiency of treatment for hepatocellular carcinoma in elderly patients」.
Professor Lee Han-ah's team compared and analyzed the survival rate (OS) according to the stage and treatment status and method of cancer by dividing 15,186 patients diagnosed with liver cancer in Korea from 2008 to 2017 into two groups: elderly patients aged 65 or older (average age 72 years, elderly patients) and non-aged patients under 65 years old (average age 54 years, non-elderly patients).
Among liver cancer patients, 25.2% of elderly patients did not receive any treatment and 16.7% of non-aged patients did not receive treatment, indicating that elderly patients often give up treatment.
However, it was found that among elderly liver cancer patients, those who received treatment had a longer average survival period than those who did not receive treatment (38.6 months vs. 22.3 months)
In particular, there was no significant difference in survival rates (66.0 months vs. 90.3 months) in elderly and non-aged patients who underwent surgery in intermediate-stage HCC and in elderly and non-aged patients who received transcatheter chemoembolization (TACE) treatment (36.5 months vs. 37.2 months), and in advanced-stage HCC, there was no significant difference in survival rates (28.4 months vs. 33.5 months) and chemotherapy (S) in elderly and non-aged patients who underwent transcatheter arterial therapy (TACE) (28.4 months vs. 33.5 months).3 months) were all found to be similar.
As a result, the research team confirmed that elderly liver cancer patients can achieve the same treatment effect as non-aged patients through active and patient-tailored treatment.
Professor Lee Han-ah of the Department of Gastroenterology at Chung-Ang University Hospital said "This study identified the current status of treatment for elderly liver cancer patients, which is increasing recently, and found that elderly liver cancer patients can achieve the same treatment effect as non-aged patients with active and customized treatment according to the patient's condition.""Even older people in their 70s and older who have been diagnosed with liver cancer, 40% of older patients with advanced liver cancer give up treatment despite having similar treatment effects as patients in their 50s."
Professor Lee Han-ah then explained, `In this study, it can be confirmed that elderly liver cancer patients who received active treatment have improved survival rates compared to those who did not receive treatment, and because they have the same survival rate as non-aged patients, even elderly people need to receive active treatment through carotid artery treatment or targeted cancer treatment and immunotherapy," he stressed.
Meanwhile, this research paper by Professor Lee Han-ah of the Department of Gastroenterology at Chung-Ang University Hospital was published in the Journal of Liver Cancer Society, and on June 29th, he won the JLC-Paper Award at the 2024 International Conference on Liver Week 2024 in recognition of the excellence of the paper.
Professor Lee Han-ah is a professional researcher in the field of chronic hepatitis B and metabolic abnormalities and consistently publishes research papers in world-renowned journals, and serves as an associate of the Publication Committee of the Korean Liver Association, an academic member of the Korean Liver Association, and a planning member, and is actively engaged in treatment and research activities in the field of liver disease.
|
bellho@sportschosun.com
